Show simple item record

dc.contributor.advisorAzam, Faruque
dc.contributor.authorShobnam, Sohana
dc.date.accessioned2024-10-24T05:01:32Z
dc.date.available2024-10-24T05:01:32Z
dc.date.copyright©2024
dc.date.issued2024-05
dc.identifier.otherID 20146042
dc.identifier.urihttp://hdl.handle.net/10361/24396
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 15-17).
dc.description.abstractMetastatic breast cancer requires more investigation because of its high incidence. Efforts to improve the accessibility, evaluative simplicity, and predictive accuracy of clinical trial endpoints are ongoing. In this paper, we analyzed 410 Phase II clinical trials’ endpoints to assess the efficacy and impact of anticancer agents. We estimated the treatment effects for overall survival and progression-free survival using appropriate statistical methodologies. We found a significant moderate positive correlation between OS and PFS (r = 0.63, 95% CI 0.55–0.71, P < 0.001). Moreover, PFS predicted the OS with a 40% accuracy (R-sq= 0.40). Interestingly, PFS showed significant differences in 1-2-and-3-agent trials, however, this was not reflected in the OS for 2-and-3-agent trials, indicating the need for further validation of the surrogacy of PFS. Nonetheless, PFS is somewhat reliable surrogate of OS in phase II trials of breast cancer and we recommend finding a better surrogate than PFS.en_US
dc.description.statementofresponsibilitySohana Shobnam
dc.format.extent17 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectPhase II trialsen_US
dc.subjectBreast canceren_US
dc.subjectEfficacy endpointsen_US
dc.subjectProgression-free survivalen_US
dc.subject.lcshBreast Cancer.
dc.subject.lcshBreast Cancer--Survival.
dc.titlePooled analysis of progression-free survival and overall survival in phase II clinical trials of breast canceren_US
dc.typeThesisen_US
dc.contributor.departmentSchool of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record